Interactions on record — worth a quick check against your medications. Based on 4 of 12 ingredients. Check your meds →
Dietary supplement

PB 12/30 Ingredients & Drug Interactions

by Bairn Biologics

Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

PB 12/30 is a dietary supplement by Bairn Biologics with 12 active ingredients. Its ingredients are commonly taken for digestive health and regularity, irritable bowel syndrome (ibs), diarrhea (including antibiotic-related).Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium longum (ATCC # SD5588), Bifidobacterium bifidum (ATCC # SD6576), Lactobacillus acidophilus (ATCC # SD5212). Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of PB 12/30 by Bairn Biologics

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 12 active ingredients.
  • “Bifido Probiotic Cultures” is listed as a grouped ingredient — the label doesn't break down how much of each component you get.
  • “Lacto Probiotic Cultures” is listed as a grouped ingredient — the label doesn't break down how much of each component you get.

PB 12/30 contains 12 active probiotic ingredients — a mix of Bifidobacterium and Lactobacillus species, both friendly bacteria that live in the gut. The Bifidobacterium group includes B. longum, B. infantis, and B. bifidum.

The Lactobacillus group includes L. acidophilus, L. paracasei, L. brevis, L. bulgaricus, L. salivarius, L. plantarum, L. rhamnosus, and L. casei. The inactive ingredients are microcrystalline cellulose (a binder), a vegetable capsule, L-leucine, and silicon dioxide.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: digestive health, gas, bloating, and constipation.
  • We looked for evidence on: Antibiotic-associated diarrhea, Constipation, Diarrhea, Irritable bowel syndrome (IBS), Lactose intolerance, Gut microbiome balance — and 1 related terms.
  • The strongest evidence on file: Lactobacillus Acidophilus is rated "Possibly Effective" for Antibiotic-associated diarrhea (Natural Medicines).
  • Also on file: Lactobacillus Acidophilus is rated "Possibly Effective" for Irritable bowel syndrome (IBS).
  • Also on file: Bifidobacterium Bifidum is rated "Possibly Effective" for Irritable bowel syndrome (IBS).

The evidence for most conditions isn't established yet. Bifidobacterium bifidum and Lactobacillus acidophilus are rated possibly effective for irritable bowel syndrome (IBS) and some other conditions — L. acidophilus also shows possibly effective evidence for antibiotic-associated diarrhea, H. pylori, and bacterial vaginosis.

For the other bacteria in this blend and most other health claims, the data we hold shows insufficient reliable evidence to rate them.

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 4 of the 4 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 4 of 4.
  • General safety write-ups exist for 4 of 4.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

These probiotics are generally well tolerated in healthy people, though those with weakened immune systems should be cautious. Rarely, people have reported mild gastrointestinal side effects like abdominal discomfort, bloating, flatulence, and constipation — and in very rare cases, serious infections in critically ill or immune-compromised patients.

Bifidobacterium bifidum and Lactobacillus acidophilus are rated possibly safe in pregnancy; for Lactobacillus bulgaricus, the data notes that probiotic supplements in pregnancy aren't well studied, so talk with your doctor. Limited data exist for breastfeeding, so check with your healthcare provider first.

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 4 of the 4 matched ingredients can interact with medications — Lactobacillus Acidophilus, Bifidobacterium Bifidum, Bifidobacterium Longum, Lactobacillus Delbrueckii.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Antibiotic drugs are the key medication type to check before taking this product — they're rated Moderate-severity interactions with at least four of the probiotic strains in PB 12/30. If you're on antibiotics, ask your doctor or pharmacist about timing: they may want you to separate when you take them from when you take the probiotic.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

PB 12/30 is a multi-strain probiotic aimed at gut health — particularly IBS — though evidence for most of its ingredients is still thin. The main concern is taking it with antibiotics: space them apart so the antibiotics don't kill off the live bacteria.

If you take any medications, check them against the list on this page before you start, and talk it over with your doctor or pharmacist, especially if you're seriously ill, immunocompromised, pregnant, or breastfeeding.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 4 of 12 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Jul 23, 2020.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about PB 12/30, straight from the product label.

Brand Bairn Biologics
Barcode (UPC) 857021590023
Net contents 60 Delayed-Release Vegetarian Capsule(s)
Market status On market
Date entered into DSLD Jul 23, 2020
DSLD ID 230682
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Children 4 or More Years of Age, Vegetarian, Adult (18 - 50 Years), Gluten Free, Dairy Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for PB 12/30 by Bairn Biologics, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
UPC/BARCODE
857021590023
IngredientAmount% DV
Bifido Probiotic Cultures0 NP--
Bifidobacterium lactis (ATCC # SD5219)0 NP--
Bifidobacterium infantis (ATCC # SD6720)0 NP--
Bifidobacterium longum (ATCC # SD5588)0 NP--
Bifidobacterium bifidum (ATCC # SD6576)0 NP--
Lacto Probiotic Cultures0 NP--
Lactobacillus acidophilus (ATCC # SD5212)0 NP--
Lactobacillus paracasei (ATCC # SD5275)0 NP--
Lactobacillus brevis (ATCC # SD5214)0 NP--
Lactobacillus bulgaricus (ATCC # SD5589)0 NP--
Lactobacillus salivarius (ATCC # SD5208)0 NP--
Lactobacillus plantarum (ATCC # SD5209)0 NP--
Lactobacillus rhamnosus (ATCC # SD5217)0 NP--
Lactobacillus casei (ATCC # SD5213)0 NP--

Other ingredients: Microcrystalline Cellulose, Vegetable Capsule, L-Leucine, Silicon Dioxide

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Formula

Aging, stress, poor diet, x-rays, alcohol, and many other frequently encountered substances can deplete the probiotic cultures that inhabit the human gut. Such depletion can lead to gas, bloating, occasional constipation, and poor digestion. PG 12/30 combines 12 probiotic strains (at least 30 billion active cultures per capsule) to replace these lost cultures. It is one of the most advanced daily probiotics ever offered.

For Men and Women Ages 16-39

12 strains, 30 billion cultures per capsule

PB 12/30 is formulated to provide at least 30 billion live cultures per capsule at date of expiration if stored under recommended conditions.

Storage

Storage: To assure maximum potency, please keep this product refrigerated.

To assure maximum potency, please keep this product refrigerated.

Precautions

Caution: Consult your physician before using this or any product if you are pregnant, nursing, trying to conceive, taking medication or have a known medical condition.

Please keep all supplements out of children’s reach.

Formulation

Guarantee: PB 12/30 does not contain artificial colorings or flavorings, GMOs, soy, dairy, gluten, or wheat, and is suitable for vegetarians.

Supports immune & digestive health Potency assured

Dairy & gluten free

Guarantee: PB 12/30 does not contain artificial colorings or flavorings, GMOs, soy, dairy, gluten, or wheat, and is suitable for vegetarians.

General Statements

We guarantee our products to your complete satisfaction. If you are anything but delighted, please return the unused portion of your product with receipt to your retailer.

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Brand IP Statement(s)

2014 all rights reserved.

FDA Statement of Identity

Probiotic Supplement

Suggested/Recommended/Usage/Directions

Suggested Use: For best results, take one capsule daily with your lightest meal.

See for yourself

PB 12/30 by Bairn Biologics label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

What’s inside

The Ingredients in PB 12/30 by Bairn Biologics

These are the 12 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Bifido Probiotic Cultures

0 NP per serving

Lacto Probiotic Cultures

0 NP per serving

Other (inactive) ingredients: Microcrystalline Cellulose, Vegetable Capsule, L-Leucine, Silicon Dioxide. These complete the product’s ingredient list but are not active constituents.

Interaction report

PB 12/30 by Bairn Biologics Drug Interactions

Want to check YOUR meds against PB 12/30?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker

Each ingredient & the kinds of drugs it affects

For each ingredient in PB 12/30 with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium longum (ATCC # SD5588)1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium longum with antibiotic drugs might decrease the effectiveness of B. longum.
Since B. longum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. longum preparations by at least 2 hours.

Likelihood Probable Evidence D

Bifidobacterium bifidum (ATCC # SD6576)1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium. bifidum with antibiotic drugs might decrease the effectiveness of B. bifidum.
Since B. bifidum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. bifidum preparations by at least 2 hours.

Likelihood Probable Evidence D

Lactobacillus acidophilus (ATCC # SD5212)1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus acidophilus with antibiotic drugs might decrease the effectiveness of L. acidophilus.
L. acidophilus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. acidophilus preparations by at least two hours.

Likelihood Probable Evidence D

Lactobacillus bulgaricus (ATCC # SD5589)1 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus delbrueckii with antibiotic drugs might decrease the effectiveness of L. delbrueckii.
Lactobacillus delbrueckii preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. delbrueckii preparations by at least two hours.

Likelihood Probable Evidence D
The maker

Brand information

Manufacturer and brand details for PB 12/30, from the product label.

Bairn Biologics

See all Bairn Biologics products
Name
Bairn Biologics
Street Address
P.O. Box 95966
City
Las Vegas
State
NV
ZipCode
89193
Web Address
www.bairnbiologics.com
Pharmacist Counseling Corner

PB 12/30 by Bairn Biologics: Common Questions

Does PB 12/30 by Bairn Biologics interact with any medications?
Yes. Based on its ingredients, PB 12/30 has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
PB 12/30 contains 12 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take PB 12/30 while I'm on antibiotics?
The probiotics in PB 12/30 are live organisms, and antibiotics can kill them, reducing how well the probiotic works. Talk with your doctor or pharmacist about spacing them out — they might recommend taking them at different times of day.
Is PB 12/30 safe if I'm pregnant or breastfeeding?
Bifidobacterium bifidum and Lactobacillus acidophilus are rated possibly safe in pregnancy, but for other strains in this blend, the data are limited. Check with your doctor or pharmacist before use during pregnancy or breastfeeding — they can give you personalized guidance.
Does PB 12/30 actually work for IBS?
Two of the strains in this blend — Bifidobacterium bifidum and Lactobacillus acidophilus — are rated possibly effective for irritable bowel syndrome, based on the evidence we hold. The other strains don't yet have that level of support.
What are the live cultures in this formula?
PB 12/30 contains two groups: Bifido Probiotic Cultures (Bifidobacterium longum, B. infantis, and B. bifidum) and Lacto Probiotic Cultures (eight Lactobacillus species: L. acidophilus, L. paracasei, L. brevis, L. bulgaricus, L. salivarius, L. plantarum, L. rhamnosus, and L. casei).
Are there any common side effects?
Most people tolerate these probiotics well. Rarely, people report mild gastrointestinal symptoms like bloating, gas, abdominal discomfort, or constipation when first starting. These usually settle down.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if PB 12/30 is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

PB 12/30 label
Sources

Sources & How We Checked

PB 12/30's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 52 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Bifidobacterium Bifidum 7 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Rerksuppaphol S, Rerksuppaphol L. Randomized controlled trial of probiotics to reduce common cold in schoolchildren. Pediatr Int. 2012;54(5):682-7. PubMed
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  6. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  7. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed

See these in context on the Bifidobacterium Bifidum monograph →

Lactobacillus Acidophilus 15 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome--a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48(10):1127-35 PubMed
  3. Chatterjee S, Kar P, Das T, Ray S, Gangulyt S, Rajendiran C, Mitra M. Randomised placebo-controlled double blind multicentric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated
  4. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M,Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-c
  5. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  6. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  7. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Xiao SD, Zhang DZ, Lu H, et al. Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther. 2003;20(5):253-60.
  10. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  11. Ozer M, Goksu SY, Shahverdiani A, Mustafa M. Lactobacillus acidophilus-induced endocarditis and associated splenic abscess. Case Rep Infect Dis 2020;2020:1382709.
  12. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liver Dis 2020;52(5):534-540. PubMed
  13. Stoffer JN, Slingsby TJ, Giuliari GP. Lactobacillus acidophilus endophthalmitis after intravitreal bevacizumab injection requiring intraocular lens explantation. Can J Ophthalmol 2022;57(1):e21-e22. PubMed
  14. Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 2006;73(2-3):107-10.
  15. Hui J, Ren Y, Wang Y, Han Q. Lactobacillus acidophilus endophthalmitis postcataract operation: A case report with a literature review. Ocul Immunol Inflamm 2023.

See these in context on the Lactobacillus Acidophilus monograph →

Lactobacillus Delbrueckii 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  3. Ranchal P, Gupta R, Goldberg R, A Lobo S, Pascual A, El Khoury MY. Penicillin-sensitive Lactobacillus jensenii bacteremia. Am J Ther 2021;28(2):e250-e252. PubMed
  4. Grazioli-Gauthier L, Rigamonti E, Leo LA, Martinetti Lucchini G, Lo Priore E, Bernasconi E. Lactobacillus jensenii mitral valve endocarditis: Case report, literature review and new perspectives. IDCases 2022;27:e01401. PubMed
  5. Toprak NU, Bozan T, Yilmaz S, Buyukbayrak EE, Tigen ET. Polymicrobial bacteremia due to Lactobacillus jensenii and Veillonella montpellierensis in a pregnant patient; case report and review of literature. Anaerobe 2022;75:102576. PubMed
  6. Chazan B, Raz R, Shental Y, Sprecher H, Colodner R. Bacteremia and pyelonephritis caused by Lactobacillus jensenii in a patient with urolithiasis. Isr Med Assoc J 2008;10(2):164-5.
  7. Neonakis IK, Skamagkas I, Stafylaki D, Maraki S. Lactobacillus delbrueckii urinary tract infection in a male patient: a case report. Germs 2022;12(2):304-307. PubMed
  8. Maillet F, Passeron A, Podglajen I, Ranque B, Pouchot J. Lactobacillus delbrueckii urinary tract infection in a male patient. Med Mal Infect 2019;49(3):226-228. PubMed
  9. Darbro BW, Petroelje BK, Doern GV. Lactobacillus delbrueckii as the cause of urinary tract infection. J Clin Microbiol 2009;47(1):275-7.

See these in context on the Lactobacillus Delbrueckii monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring